The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough

Hepatology

Volumn 35, Issue 2, 2002, Pages 478-491

  Wiest, Reiner ^a   Groszmann, Roberto J ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLATE CYCLASE; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ARTICLE; ATHEROSCLEROSIS; CHEMICAL REACTION; CHRONIC LIVER DISEASE; COLLATERAL CIRCULATION; DNA STRAND; ENDOTOXEMIA; EXTRACELLULAR MATRIX; HYDROPHOBICITY; HYPERCHOLESTEROLEMIA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER PERFUSION; LIVER SINUSOID; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW;

EID: 0036154951     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.31432     Document Type: Article

References (177)

1. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators
2. Verapamil favouràbly influences hepatic microvascular exchange and function in rats with cirrhosis of the liver
3. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor
4. Regulatory functions of vascular endothelium
5. The nitric oxide synthase family of proteins
6. Constitutive nuclear factor-kappa B activity in human upper airway tissues and nasal epithelial cells
7. Mechanotransduction in endothelial cells: Temporal signaling events in response to shear stress
8. Elevated portal pressure in mice with targeted disruptio of the gene for endothelial nitric oxide sythase
9. Endothelial dysfunction in the intrahepatic microcirculation of cirrhotic rats
10. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat
11. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis
12. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension
13. Distribution of neuronal nitric oxide synthase in the rat liver
14. Nitric oxide, superoxide, and peroxynitrite: The good, the bad and the ugly
15. Nitric oxide release from a single cell measured in situ by a prophyrinic-based microsensor
16. Role of nitric oxide formation in the regulation of haemodynamics and the release of noradrenaline and adrenaline
17. Nitric oxide modulates vascular tone in normal rat liver
18. NO-mediated vasodilation in the rat liver. Role of hepatocytes and liver endothelial cells
19. Nitric oxide mediates hepatic arterial vacular escape from norepinephrine-induced constriction
20. Nitric oxide modulates both pre-sinusoidal and sinusoidal responses to phenylephrine in normal rat liver
21. Nitric oxide plays a greater role on the sinusoidal than pre-sinusoidal increased vascular resistance in cirrhotic rat liver
22. Shear stress-induced release of nitric oxide from endothelial cells grown on beads
23. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress
24. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids
25. The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase
26. Aminoethylisothiourea, a selective inhibitor of inducible nitric oxide synthase activity, improves liver circulation and oxygen metabolism in a porcine model of endotoxemia
27. Endothelin-1 and Endothelin-3 in cirrhosis: Relations to systemic and splanchnic haemodynamics
28. Endothelin-1 induces direct constriction of hepatic sinusoids
29. Endothelin induced contractility of stellate cell from normal and cirrhotic rat liver: Implication for regulation of portal pressure and resistance
30. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells
31. Gene expression of endothelin-1 and ETa and ETb receptors in human cirrhosis: Relationship with hepatic hemodynamics
32. Endothelial dysfunction in atherosclerosis
33. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
34. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
35. Atherosclerosis and the two faces of endothelial nitric oxide synthase
36. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
37. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation
38. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans
39. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension
40. Nitric oxide: An endogenous modulator of leukocyte adhesion
41. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action
42. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation
43. Roles of oxidative stress in activation of kupffer and Ito cells
44. Stimulation of lipid peroxidation or 4-hydroxynoneal treatment increases procollagen alpha 1 (I) gene expression and synthesis in human fat-storing cells
45. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride
46. Vascular endothelial cell regulation of extracellular matrix collagen: Role of nitric oxide
47. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: Role of nitric oxide
48. Multiple organ failure
49. Pathophysiology and potential future therapy
50. Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance
51. S-nitrosylation: Spectrum and specificity
52. Nitric oxide I :Physiological chemistry of nitric oxide and its metabolites: Implications in inflammation
53. Nitric oxide activates cyclooxygenase enzymes
54. Nitric oxide as a secretory product of mammalian cells
55. Biochemistry of nitric oxide and its redox-activated forms
56. In the CC14 cirrhosis but not in pre-hepatic portal hypertension or biliary cirrhosis, a reduced expression of CENOS is found in rat liver
57. Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-en Y choledochojejunostromy in the rat
58. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide
59. Targeting of nitric oxide synthase to endothelial caveolae via palmitoylation: Implications for nitric oxide signaling
60. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1
61. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase
62. Molecular control of nitric oxide synthases in the cardiovascular system
63. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase
64. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin
65. 2+-calmodulin and caveolin
66. Caveolin-1 in normal and cirrhotic human liver
67. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
68. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
69. Regulation of cholesterol and bile acid homeostasis in bile-obstructed rats
70. Liver fibrosis in overweight patients
71. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol
72. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication
73. Improvement of nitric-oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
74. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
75. Administration of L-arginine, the physiological precursor of nitric oxide, reduces portal perfusion pressure and ameliorates hepatic vascular hyperreactivity in experimental cirrhosis
76. Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis
77. Biosynthesis of nitric oxide: Dependence on pteridine metabolism
78. Oxygen radical stress in vascular disease: The role of endothelial nitric oxide synthase
79. Endothelial dysfunction in atherosclerotic mice: Improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin
80. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein
81. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia
82. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats
83. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase
84. Antiatherosclerotic activity of drugs in relation to nitric oxide function
85. How does ascorbic acid prevent endothelial dysfunction?
86. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension
87. The nitrovasodilators: New ideas about old drugs
88. Bioactivation of nitroglycerin and vasomotor response to nitric oxide is impaired in cirrhotic rat livers
89. β-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: The good, the bad, the ugly
90. Targeting nitric oxide delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis-alpha-induced apoptosis and toxicity in the liver
91. Chronic hemodynamic effects of a new liver specific no donor (V-PYRRO/NO) in bile duct ligated (BDL) rats
92. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension
93. CENOS gene transfer enhances NO production and NOS protein expression in the CC14 cirrhotic rat liver resulting in prolonged decrease of portal pressure
94. Hyperdynamic circulation of liver diseases forty years later: Pathophysiology and clinical consequences
95. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension
96. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model
97. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
98. Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation
99. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats
100. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats
101. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats
102. Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis
103. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
104. Hyposensitivity to nerve stimulation in portal hypertensive rats: Role of nitric oxide
105. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis
106. Increased nitric oxide release in response to vasoconstrictors in the superior mesenteric arterial bed of cirrhotic rats
107. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites
108. Upregulation of endothelial constitutive NOS: A major role in the increased NO production in cirrhotic rats
109. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats
110. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats
111. Enhanced nitric oxide synthase activity in portal hypertensive rabbits
112. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats
113. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow
114. Nitric oxide overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats
115. Dynamic activation of endothelial nitric oxide synthase by Hsp90
116. HSP 90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension
117. Signal transduction of eNOS activity
118. The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension
119. Hyperdynamic circulation in cirrhosis: A role for nitric oxide?
120. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites
121. Evidence against a role for inducible nitric oxide synthase in the hyperdyamic circulation of portal-hypertensive rats
122. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats
123. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds
124. Inducible nitric oxide synthase from rat alveolar cell line is inhibited by nitric oxide
125. Abnormal regulation of aortic NOS2 and NOS3 activity and expression from portal vein-stenosed rats after lipopolysaccharide administration
126. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia
127. Hyperdynamic circulation of cirrhotic rats with ascites: Role of endotoxin, tumour necrosis factor and nitric oxide
128. The endogenous cannabinoid system: A novel and potent regulator of systemic and portal hemodynamics in normal and cirrhotic rats
129. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in cirrhosis
130. Bacterial translocation to mesenteric lymph nodes enhances eNOS-derived NO overproduction in mesenteric vasculature of cirrhotic rats: Role for impairment in vascular contractility
131. Thalidomide inhibits tumor necrosis factor-α, decreases nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal hypertensive rats
132. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin
133. Tumor necrosis factor a: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats
134. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity
135. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells
136. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS
137. Bacterial translocation to mesenteric lymph nodes induces endotoxemia and stimulates GTP-Cyclohydrolase I in mesenteric vasculature of cirrhotic rats
138. Hyperdynamic circulation in patients with cirrhosis: Direct measurement of nitric oxide levels in hepatic and portal veins
139. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure
140. Systemic and regional hemodynamics in pre-ascitic cirrhosis
141. Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats
142. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats
143. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: Role of nitric oxide and endothelium
144. Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites
145. Enhanced endothelium-dependent vasodilation in patients with cirrhosis
146. Studies on the acute cardiovascular effects of intravenous sodium nitroprusside
147. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertensive rats
148. Peripheral arterial vasodilatation hypothesis: A proposal for the initiation of renal sodium and water retention
149. Renal effects of nitric oxide synthesis inhibition in cirrhotic rats
150. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide
151. Nω-nitro-L-arginine administration corrects vasodilatation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats
152. Pharmacology of portal-systemic collaterals in portal hypertensive rats: Role of endothelium
153. Administration of Nω-nitro-L-arginine ameliorates portal-systemic shunting in portal hypertensive rats
154. The porto-systemic collateral pattern in the rat: An angiographic and anatomic study after partial occlusion of the portal vein
155. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance
156. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
157. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells
158. Portal venous pressure and portasystemic shunting in experimental portal hypertension
159. Hemostasis in liver disease
160. A Prolonged bleeding time in experimental cirrhosis: Role of nitric oxide
161. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries
162. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries
163. Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat
164. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
165. Cytokines and fibrogenesis
166. Cytokine regulation of endothelial cells function
167. Hepatic stellate cells and intrahepatic modulation of portal pressure
168. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
169. Human atherosclerosis. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults
170. Hypercholesterolemia increases endothelial superoxide anion production
171. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury
172. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits
173. Pathogenesis of liver fibrosis: Role of oxidative stress
174. Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress
175. Lipid peroxidation and endothelial cell injury: Implications in atherosclerosis
176. Peroxidation of lipids and liver damage